The Christopher & Dana Reeve Foundation's North American Clinical Trials Network (NACTN), with funding from the Department of Defense (DOD), is partnering with AOSpine North America in RISCIS (Riluzole in Spinal Cord Injury Study). The Phase II/III clinical trial is a multi-center, randomized, placebo-controlled double-blinded study that will enroll 351 patients with acute cervical spinal cord injuries. The DOD funding also enables NACTN sites to conduct a RISCIS sub-study, the pharmacology of riluzole, to determine optimal dosage of the drug.
Learn more by visiting our Research page.